Welcome to the ICON7 website
This website is designed to provide you with information about the ICON7 Trial.The website will serve primarily as a platform for sharing information between collaborators and members of the Trial Management Group
Click here to learn more about ICON7
News
December 2011
ICON7 Progression Free Survival results and interim Overall Survival results have been published in the New England Journal of Medicine on 29th December 2011.Original Article, N Engl J Med 2011 ; 365 : 2484 - 2496
GCIG Gynaecologic Cancer Intergroup trial
ICON7 - A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer.ICON7 is an international trial performed through the Gynecologic Cancer InterGroup (GCIG). The MRC/NCRI Group is the lead group and the MRC Clinical Trials Unit will coordinate the trial.
The trial will be conducted with the following GCIG Groups:
MRC/NCRI - Medical Research Council/National Cancer Research Institute
AGO - AGO Studiengruppe Ovarialkarzinom (Germany)
ANZGOG - Australia/New Zealand Gynecologic Oncology Group
GEICO - Grupo Espanol de Investigacion en Cancer de Ovario (Spain)
GINECO - Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (France)
NCIC CTG - National Cancer Institute of Canada Clinical Trial Group
NSGO - Nordic Society of Gynecologic Oncology
Click here to access the GCIG groups area on ICON7